Asia-Pacific Insulin Market Scrutinized by Ken Research Private in In-demand Report Available at MarketPublishers.com23 Dec 2014 • by Natalie Aster
LONDON – By 2035, the global incidence of diabetes is anticipated to rise by 55% and is set to achieve 591.1 million patients. The changes in dietary regimes and lack of physical activity are the main reasons provoking the disease expansion. The countries with low and middle incomes comprise 80% of all the diabetic cases in the world.
Most of the diabetic patients reside in the APAC region, primarily in India and China. These countries have the highest number of people suffering from diabetes worldwide. As the Asian countries reside primarily in the middle income group, the treatment together with diagnosis of diabetes often cannot reach to a large number of patients in these countries. In spite of some hindrances to curbing diabetes in the APAC region (such as lack of affordability and awareness), the level of education and consciousness in the Asia-Pacific countries is increasing, therefore, people begin to pay much more attention to diabetes diagnosis and care.
The insulin demand is constantly rising in the APAC region, with Japan holding dominance in the global market for insulin in terms of value, as the country is engaged in the manufacturing of high-priced premium products. Regional market players are currently working on new products to satisfy the local demand. Besides, given the expirations of major insulin companies' patents, the competition will grow in the region in the future.
Topical market research report “Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin” elaborated by Ken Research Private Ltd. includes an insightful analysis of the Asia-Pacific market for insulin. The in-demand report provides the insulin market segmentation analysis by main geographical regions, by insulin type and insulin replacement therapy. It examines the major trends, driving the insulin market growth in Asia-Pacific, overviews the product pipelines of the main companies and discusses the governmental regulations. The detailed profiles of the main insulin producers can also be found in the study. Additionally, it analyses the pricing trends and describes the recent developments within the market. Future outlook for the Asia-Pacific insulin market is provided as well.
Asia Pacific Insulin Market Review to 2018 - Transition from Human Insulin to Analog Insulin
Published: September, 2014
Price: US$ 1,500.00
More topical research reports by the publisher can be found at Ken Research Private page.